Iguratimod

(Synonyms: T614)
5 Cited Publications
Customer Review

Based on 5 publication(s) in Google Scholar

Iguratimod (T614) is an orally active anti-rheumatic agent. Iguratimod modulates T and B lymphocytes, inhibits the production of inflammatory cytokines and autoantibodies, and downregulates T cell-dependent cellular immunity. Iguratimod targets the IL-17 signaling axis, reduces MAPK phosphorylation and the mRNA stability of pro-inflammatory genes in fibroblast-like synoviocytes, and alleviates synovial inflammation in collagen-induced arthritis. Iguratimod blocks RANKL- and TNF-α-induced osteoclastogenesis by inhibiting the p38, ERK, and NF-κB signaling pathways, suppresses the bone resorption function of mature osteoclasts, and protects ovariectomized mice from bone loss. Iguratimod inhibits MIF tautomerase activity and exerts a steroid-sparing effect. Iguratimod inhibits COX-2, reduces PGE2 release, and also possesses anti-pulmonary fibrosis effects. Iguratimod can be used in research on various diseases such as rheumatoid arthritis, systemic lupus erythematosus, and interstitial lung disease.

For research use only. We do not sell to patients.

  • Purity : 99.95%
  • CAS No.: 123663-49-0
  • Formula: C17H14N2O6S
  • Molecular Weight:374.37
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00